🇺🇸 FDA

Intelligence Platform

Patents

Browse 454 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8889661

Treatment of lupus nephritis using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8889627

Treatment of multiple sclerosis with combination of laquinimod and fingolimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8884014

Method for purifying a fused pyrrolocarbazole derivative

Teva Sante · Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8865722

Wet formulations of aripiprazole

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8815511

Determination of single nucleotide polymorphisms useful to predict response for glatiramer

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8809537

N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8809310

Use of rasagiline for the treatment of multiple system atrophy

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8802854

Crystalline forms of Prasugrel salts

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8759302

Methods of treating a subject afflicted with an autoimmune disease using predictive biomar

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8759314

Methods for treating multiple sclerosis using antisense oligonucleotides

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8742129

Crystalline forms of febuxostat

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8729305

Process for the preparation of and crystalline forms of optical enantiomers of modafinil

Teva Sante · Granted Tue May 20 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8722722

Raltegravir salts and crystalline forms thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 13 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8722863

Solid state forms of fidaxomycin and processes for preparation thereof

Teva Pharmaceutical Works Ltd. · Granted Tue May 13 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8709433

Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8691872

Dispersions of rasagiline citrate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8680084

Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology

TEVA WOMEN'S HEALTH, INC. · Granted Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8673322

Crystals of laquinimod sodium, and process for the manufacture thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8663703

Drug microparticles, processes of preparing them and a drug delivery vehicle comprising th

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8663681

Oral dosage forms comprising progesterone and methods of making and using the same

TEVA WOMEN'S HEALTH, INC. · Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8653060

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8653055

Corticosteroid having low systemic absorption

Teva Animal Health, Inc. · Granted Tue Feb 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8648067

Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands

Teva Sante · Granted Tue Feb 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8647646

Crystals of laquinimod sodium, and process for the manufacture thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted